Compare Nuwellis Inc (NUWE) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Schlumberger NV — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Schlumberger NV trades at $48.89 (market cap $72.69B). The key difference: Schlumberger NV is far larger — about 33040.9× Nuwellis Inc's market cap, and Schlumberger NV pays a 2.41% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Schlumberger NV for 99 Days on average.
| NUWE | SLB | |
|---|---|---|
Market Cap | $2.20M | $72.69B |
Volume | 121,544 | 16,228,451 |
Sector | Health | Energy |
52-Week High | $146.65 | $60.10 |
52-Week Low | $0.68 | $31.72 |
Typical Hold Time | 26 Days | 99 Days |
Enterprise Value | -$1.52M | $81.42B |
Dividend Yield | — | 2.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
SLB trades at $47.96, down 4.08% on the day, amid a bearish technical signal. The company has beaten EPS estimates for the last three quarters, with Q3 2026 results pending. Recent contract wins in the Rovuma Basin, Saudi Arabia, and Oman bolster revenue visibility. Cash flow from operations remains strong at $6.49B for 2025, though net cash flow was negative due to financing activities.
Analyst consensus is bullish with an 84.85% buy rating and a $64.58 price target, implying significant upside. Risks include exposure to oil price volatility and recent profit margin compression. The stock's current valuation metrics, including a P/E of 23.89, appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
